Why Bristol Myers Squibb Stock Isn’t as Cheap as It Seems
Bristol Myers Squibb stock often appears attractively priced, with a solid dividend. But when you look under the hood...
This Pharma tag page compiles 4 recent articles on Moderna, Lilly, ANIP, and pharma dividends to help you spot opportunities and manage risk in your portfolio.
27 articlesBristol Myers Squibb stock often appears attractively priced, with a solid dividend. But when you look under the hood...
A single conference-call moment changed the mood around Eli Lilly. By unpacking eight key themes from the CEO, invest...
Could Lilly ride a Nvidia-like surge? This piece analyzes whether the stock can follow Nvidia’s AI-driven momentum, f...
A focused look at a large institutional bet on Indivior, the logic behind the $143 million investment, and how such m...
Sanofi is accelerating its internal AI push with a home grown assistant and a centralized data lake. The strategy aim...
The VanEck PPH ETF faces two key risks in 2026: heavy concentration in Eli Lilly and shifting U.S. drug pricing polic...
Eli Lilly stock fell about 5% as investors awaited the FDA's April decision on orforglipron. Novo Nordisk's intensifi...
Eli Lilly unveiled a direct-to-employer program for Zepbound, aiming to accelerate GLP-1 adoption and expand market s...
Analysts are arguing that Merck's sac-TMT program could unlock substantial upside for MRK, supported by a strong pipe...
Hims & Hers Health shifts to selling branded Wegovy and Ozempic after a settlement with Novo Nordisk, reversing regul...
GSK has seen a steep run in its stock, prompting questions about whether the rally still offers upside. This article ...
A strong pharma dividend stock could be a powerful component of a retirement plan. Learn how to choose, invest, and c...